Edition:
United Kingdom

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

129.28USD
5:09pm BST
Change (% chg)

$0.77 (+0.60%)
Prev Close
$128.51
Open
$128.67
Day's High
$130.51
Day's Low
$128.28
Volume
250,463
Avg. Vol
484,835
52-wk High
$144.91
52-wk Low
$102.21

Chart for

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $31,536.07
Shares Outstanding(Mil.): 223.19
Dividend: --
Yield (%): --

Financials

  ALXN.OQ Industry Sector
P/E (TTM): 61.23 30.93 32.76
EPS (TTM): 2.31 -- --
ROI: 4.17 15.07 14.61
ROE: 6.11 16.59 16.33

BRIEF-Alexion Reports Q1 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study

* ALEXION REPORTS FIRST QUARTER 2018 RESULTS AND POSITIVE TOPLINE DATA FROM ALXN1210 PHASE 3 PNH SWITCH STUDY

26 Apr 2018

BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil

* ALEXION PROVIDES STATEMENT ON SUPERIOR COURT OF JUSTICE (STJ) DECISION IN BRAZIL INVOLVING SOLIRIS® (ECULIZUMAB)

20 Apr 2018

Deals of the day-Mergers and acquisitions

April 11 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:

11 Apr 2018

Biotech M&A rolls on as Alexion snaps up Wilson for $855 million

Alexion Pharmaceuticals has agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues.

11 Apr 2018

Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln

Alexion Pharmaceuticals has agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues.

11 Apr 2018

UPDATE 2-Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln

* U.S. company says first step in rebuilding pipeline (Adds latest shares, analyst reaction)

11 Apr 2018

Alexion to buy Swedish biotech Wilson Therapeutics for $855 mln

April 11 Alexion Pharmaceuticals said on Wednesday it had agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million) to boost its line-up of rare disease drugs.

11 Apr 2018

BRIEF-Alexion To Acquire Wilson Therapeutics

* SAYS ALEXION WILL ACQUIRE WILSON THERAPEUTICS THROUGH A TENDER OFFER

11 Apr 2018

BRIEF-Alexion Pharmaceuticals Says CEO Ludwig Hantson's Total FY 2017 Compensation Was $15.3 Mln

* ALEXION PHARMACEUTICALS SAYS CEO LUDWIG HANTSON'S TOTAL FY 2017 COMPENSATION WAS $15.3 MILLION - SEC FILING

28 Mar 2018

Competitors

Earnings vs. Estimates